These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 16927824)

  • 1. [Identification of glufosfamide metabolites in rats].
    Sun YM; Chen XY; Zhong DF
    Yao Xue Xue Bao; 2006 Jun; 41(6):513-7. PubMed ID: 16927824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of glufosfamide in phosphate buffers and in biological samples.
    Sun Y; Chen X; Xu H; Guan Z; Zhong D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Mar; 832(2):224-30. PubMed ID: 16455312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glufosfamide (Baxter Oncology).
    Niculescu-Duvaz I
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1527-32. PubMed ID: 12431031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of glufosfamide in rat plasma by liquid chromatography/tandem mass spectrometry.
    Chen X; Sun Y; Cao X; Jin F; Zhong D
    Rapid Commun Mass Spectrom; 2005; 19(13):1839-43. PubMed ID: 15945026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
    Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
    Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent.
    Dollner R; Dietz A; Kopun M; Helbig M; Wallner F; Granzow C
    Anticancer Res; 2004; 24(5A):2947-51. PubMed ID: 15517901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation.
    Jain M; Kwon CH
    J Med Chem; 2003 Dec; 46(25):5428-36. PubMed ID: 14640551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative disposition of phosphoramide mustard and other cyclophosphamide metabolites in the mouse using the Salmonella/mutagenesis assay.
    Suling WJ; Struck RF; Woolley CW; Shannon WM
    Cancer Treat Rep; 1978 Sep; 62(9):1321-8. PubMed ID: 356985
    [No Abstract]   [Full Text] [Related]  

  • 9. Possible contribution of beta-glucosidase and caspases in the cytotoxicity of glufosfamide in colon cancer cells.
    Arafa HM
    Eur J Pharmacol; 2009 Aug; 616(1-3):58-63. PubMed ID: 19545561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat.
    Lu H; Chan KK
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):532-9. PubMed ID: 16470409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glufosfamide: beta-D-Glc-IPM, D 19575.
    Drugs R D; 2005; 6(1):49-52. PubMed ID: 15801867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Perfect drug targeting. Glufosfamide a new derivative].
    Holzgrabe U
    Pharm Unserer Zeit; 2006; 35(2):158-9. PubMed ID: 16583570
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent.
    Seker H; Bertram B; Bürkle A; Kaina B; Pohl J; Koepsell H; Wiesser M
    Br J Cancer; 2000 Feb; 82(3):629-34. PubMed ID: 10682676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
    Hong PS; Srigritsanapol A; Chan KK
    Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical factors in the action of phosphoramidic mustard alkylating anticancer drugs: roles for computational chemistry.
    Colvin ME; Sasaki JC; Tran NL
    Curr Pharm Des; 1999 Aug; 5(8):645-63. PubMed ID: 10469896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
    Hemminki K
    Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
    Struck RF; Alberts DS
    Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry.
    Yuan ZM; Smith PB; Brundrett RB; Colvin M; Fenselau C
    Drug Metab Dispos; 1991; 19(3):625-9. PubMed ID: 1680629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of reactive metabolites in drug-induced teratogenesis.
    Hales BF; Slott VL
    Prog Clin Biol Res; 1987; 253():181-91. PubMed ID: 3432286
    [No Abstract]   [Full Text] [Related]  

  • 20. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
    Giaccone G; Smit EF; de Jonge M; Dansin E; Briasoulis E; Ardizzoni A; Douillard JY; Spaeth D; Lacombe D; Baron B; Bachmann P; Fumoleau P;
    Eur J Cancer; 2004 Mar; 40(5):667-72. PubMed ID: 15010066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.